Cargando…

What Underlies the Benefit of Famotidine Formulations Used During COVID-19?

Detalles Bibliográficos
Autores principales:	Singh, Vijay P., El-Kurdi, Bara, Rood, Christopher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	by the AGA Institute 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411504/ https://www.ncbi.nlm.nih.gov/pubmed/32777281 http://dx.doi.org/10.1053/j.gastro.2020.07.051

Ejemplares similares

Mechanistic basis and therapeutic relevance of hypocalcemia during severe COVID-19 infection
por: Singh, Vijay P., et al.
Publicado: (2020)

Famotidine and Coronavirus Disease 2019
por: Freedberg, Daniel E., et al.
Publicado: (2021)

Famotidine and Mortality in Coronavirus Disease 2019
por: Sethia, Rahul, et al.
Publicado: (2021)

Association Between Famotidine Use and COVID-19 Severity in Hong Kong: A Territory-wide Study
por: Cheung, Ka Shing, et al.
Publicado: (2021)

Hypocalcemia and hypoalbuminemia during COVID-19 infection: Opportunities for therapeutic intervention
por: Singh, Vijay P., et al.
Publicado: (2020)

Formulation and Evaluation of Floating Drug Delivery System of Famotidine
por: Satishbabu, B. K., et al.
Publicado: (2010)

No Evidence Indicates Famotidine Reduces the Risk of Serious Disease in COVID-19 Patients After Propensity Score Matching: Meta-Analysis and Systematic Reviews
por: Li, Weizheng, et al.
Publicado: (2021)

Formulation development and in vitro evaluation of gastroretentive hollow microspheres of famotidine
por: Chordiya, Mayur A, et al.
Publicado: (2011)

Utility of N-Bromosuccinimide for the Titrimetric and Spectrophotometric Determination of Famotidine in Pharmaceutical Formulations
por: Zenita, O., et al.
Publicado: (2011)

Formulation and evaluation of mixed matrix gastro-retentive drug delivery for famotidine
por: Patel, Dasharath M, et al.
Publicado: (2011)

COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms
por: Malone, Robert W., et al.
Publicado: (2020)

COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms
por: Malone, Robert W., et al.
Publicado: (2021)

Mortality From Coronavirus Disease 2019 Increases With Unsaturated Fat and May Be Reduced by Early Calcium and Albumin Supplementation
por: El-Kurdi, Bara, et al.
Publicado: (2020)

Case Report: Famotidine for Neuropsychiatric Symptoms in COVID-19
por: Alper, Kenneth
Publicado: (2020)

Hydrogel Polysaccharides of Tamarind and Xanthan to Formulate Hydrodynamically Balanced Matrix Tablets of Famotidine
por: Razavi, Mahboubeh, et al.
Publicado: (2014)

Effect of Famotidine on COVID-19: Killing Virus or Opposing ARDS?
por: Hosseini, Mahnaz Sadat, et al.
Publicado: (2023)

Famotidine induced hypomagnesemia leading to hypocalcemia
por: Essrani, Rajesh, et al.
Publicado: (2020)

A method for improving the properties of famotidine
por: Zhao, Yongfeng, et al.
Publicado: (2023)

Balancing Risks and Benefits in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic
por: Kotze, Paulo Gustavo, et al.
Publicado: (2021)

Sustainable Drug Delivery of Famotidine Using Chitosan‐Functionalized Graphene Oxide as Nanocarrier
por: Mahajan, Chetan Ramesh, et al.
Publicado: (2019)

Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis
por: Kow, Chia Siang, et al.
Publicado: (2021)

Tocilizumab in COVID-19 therapy: who benefits, and how?
por: Yang, Chengliang, et al.
Publicado: (2021)

Tocilizumab in COVID-19 therapy: who benefits, and how?
por: Neumann, Avidan U, et al.
Publicado: (2021)

More Than Just Heartburn: Does Famotidine Effectively Treat Patients with COVID-19?
por: Malone, Robert W.
Publicado: (2021)

Effect of famotidine on hospitalized patients with COVID-19: A systematic review and meta-analysis
por: Chiu, Leonard, et al.
Publicado: (2021)

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
por: Upreti, Vijay V, et al.
Publicado: (2013)

Hepatitis following famotidine: a case report
por: Gupta, Nishant, et al.
Publicado: (2009)

Ventricular Tachycardia Triggered by Loperamide and Famotidine Abuse
por: Larsen, Timothy R., et al.
Publicado: (2018)

Pharmacokinetics and efficacy of intravenous famotidine in adult cattle
por: Balcomb, Christie C., et al.
Publicado: (2018)

Calling for benefit–risk evaluations of COVID-19 control measures
por: Kampf, Günter, et al.
Publicado: (2021)

Hydroxychloroquine use in COVID-19: what is the basis for baseline tests?
por: Afra, TP, et al.
Publicado: (2020)

SARS, MERS, and COVID-19: What's next?
por: Sharun, Khan
Publicado: (2020)

What comes next in the COVID-19 pandemic?
por: Fisher, Dale, et al.
Publicado: (2022)

COVID-19… What are drugs and strategies now?
por: Bellini, Valentina, et al.
Publicado: (2021)

Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series
por: Janowitz, Tobias, et al.
Publicado: (2020)

In Reply–Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis
por: Lavie, Carl J.
Publicado: (2021)

What doubts, concerns and fears about COVID-19 emerged during the first wave of the pandemic?
por: Boeger, Vinicius Silveira, et al.
Publicado: (2022)

Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients
por: Hogan II, Reed B., et al.
Publicado: (2020)

No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis
por: Cheema, Huzaifa Ahmad, et al.
Publicado: (2022)

Famotidine: A potential mitigator of mast cell activation in post-COVID-19 cognitive impairment
por: Kow, Chia Siang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t2heht45eb4mejvecbj4hs6bc9